Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reissued by equities research analysts at N+1 Singer in a research note issued on Tuesday. They currently have a GBX 275 ($3.41) price objective on the stock. N+1 Singer’s target price indicates a potential upside of 110.24% from the stock’s current price.

Several other research firms have also recently weighed in on ERGO. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 267 ($3.31) target price on shares of Ergomed PLC in a research note on Tuesday, November 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 271 ($3.36) target price on shares of Ergomed PLC in a research note on Thursday, September 22nd.

Ergomed PLC (LON:ERGO) opened at 141.00 on Tuesday. Ergomed PLC has a 52-week low of GBX 117.00 and a 52-week high of GBX 172.00. The firm has a 50 day moving average of GBX 125.69 and a 200-day moving average of GBX 125.62. The stock’s market cap is GBX 43.87 million.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The correct version of this piece of content can be accessed at

About Ergomed PLC

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Stock Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related stocks with our FREE daily email newsletter.